BreezeMeds

About BreezeMeds

BreezeMeds is one of the newest entrants in the GLP-1 telehealth space, having launched in 2026. The platform offers compounded semaglutide and compounded tirzepatide at prices ranging from $199 to $399 per month. While the pricing is within the mid-range for compounded medications, the complete absence of any external validation raises immediate concerns for our editorial team. There are no Trustpilot reviews, no Better Business Bureau listing, and virtually no independent patient feedback available anywhere online.

The onboarding experience at BreezeMeds is notably slower than most competitors, with patients reporting wait times of 2 to 3 weeks before receiving their first shipment. In a market where leading providers can have medications at your door within days, this lag is a significant drawback — particularly for patients who have already made the decision to begin treatment and are eager to start. The platform does not require or offer lab testing, which means there is no baseline bloodwork to ensure patients are safe candidates for GLP-1 therapy.

From a clinical support standpoint, BreezeMeds falls short of what we consider essential. There is no dietitian access, no nutritional guidance program, and no structured ongoing support beyond the prescribing consultation. Weight loss medications work best when paired with lifestyle modifications, and the absence of any supplementary support infrastructure suggests a bare-bones, prescription-only model that may leave patients without the tools they need for long-term success.

BreezeMeds does not accept insurance, meaning all costs are entirely out-of-pocket. For a provider with zero track record, no patient reviews, and no accreditation, asking patients to commit hundreds of dollars per month requires a significant leap of faith. Our research could not verify the credentials of their medical team or the sourcing of their compounded medications, which compounds the trust deficit.

At the time of this review, BreezeMeds simply has not been around long enough to establish credibility. While every provider has to start somewhere, the combination of a brand-new launch, no external reviews, no BBB presence, slow fulfillment, and limited clinical infrastructure makes it difficult for our editorial team to recommend this provider with any confidence. We will revisit this review as the company matures and more patient data becomes available.

At a Glance